Gongwin Biopharm Holdings Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	968.9	893.47	273.59	671.51	454.12
Short-Term Investments	234.3	848.99	668.66	434.1	372.2
Trading Asset Securities	463.03	466.79	-	-	-
Cash & Short-Term Investments	1,666	2,209	942.25	1,106	826.33
Cash Growth	-24.58%	134.47%	-14.78%	33.80%	-20.45%
Accounts Receivable	16.53	14.17	10.58	-	-
Other Receivables	8.35	12.31	4.52	4.25	0.06
Receivables	24.87	26.48	15.1	4.25	0.06
Inventory	0.89	3.59	11.93	0.21	-
Prepaid Expenses	18.62	12.89	11.36	11.11	-
Other Current Assets	157.82	180.62	138.42	215.88	93.74
Total Current Assets	1,868	2,433	1,119	1,337	920.12
Property, Plant & Equipment	320.85	330.89	118.32	245.05	246.76
Long-Term Investments	487.24	497.81	156.61	32.35	3.88
Other Intangible Assets	0.83	0.37	0.19	-	-
Other Long-Term Assets	119.68	120.3	121.17	7.47	1.12
Total Assets	2,797	3,382	1,515	1,622	1,172
Accounts Payable	0.13	0.21	0.29	-	-
Accrued Expenses	38.4	28.81	26.37	32.63	21.97
Short-Term Debt	117.37	110.63	75.02	134.55	113.06
Current Portion of Leases	3.12	3.21	2.12	5.01	1.99
Current Income Taxes Payable	15.87	15.7	15.13	15.44	15.2
Other Current Liabilities	5.53	23.6	7.44	3.62	2.54
Total Current Liabilities	180.42	182.16	126.36	191.26	154.75
Long-Term Leases	9.25	12.91	0.03	2.18	0.1
Long-Term Unearned Revenue	50.41	45.01	45.08	42.03	29.57
Other Long-Term Liabilities	39.12	41.76	32.06	13.24	0
Total Liabilities	279.2	281.84	203.53	248.7	184.43
Common Stock	1,275	1,275	1,133	1,131	1,099
Additional Paid-In Capital	3,500	3,500	1,644	1,634	1,061
Retained Earnings	-1,646	-1,529	-1,441	-1,349	-1,094
Treasury Stock	-532.98	-166.61	-	-	-
Comprehensive Income & Other	-64.88	27.14	-21.35	-24.77	-95.34
Total Common Equity	2,531	3,107	1,315	1,392	970.72
Minority Interest	-13.11	-6.2	-3.68	-18.58	16.74
Shareholders' Equity	2,518	3,100	1,312	1,373	987.45
Total Liabilities & Equity	2,797	3,382	1,515	1,622	1,172
Total Debt	129.74	126.75	77.17	141.74	115.14
Net Cash (Debt)	1,536	2,082	865.08	963.87	711.19
Net Cash Growth	-26.22%	140.73%	-10.25%	35.53%	-29.07%
Net Cash Per Share	12.45	17.24	7.64	8.67	6.49
Filing Date Shares Outstanding	122.62	126.06	113.34	113.09	109.92
Total Common Shares Outstanding	122.62	126.06	113.34	113.09	109.92
Working Capital	1,688	2,251	992.7	1,146	765.37
Book Value Per Share	20.64	24.64	11.61	12.31	8.83
Tangible Book Value	2,530	3,106	1,315	1,392	970.72
Tangible Book Value Per Share	20.63	24.64	11.61	12.31	8.83
Land	228.65	228.65	49.69	155	155
Buildings	76.22	75.29	52.95	69.59	69.23
Machinery	62.62	62.66	63.43	56.76	54.91
Construction In Progress	-	-	-	-	0.54
Leasehold Improvements	10.99	11.3	3.75	3.75	3.75

Source: S&P Global Market Intelligence. Standard template. Financial Sources.